Manuela Buxo To Become Head of Sanofi’s (SNY) Specialty Care Global Business Unit

SNY -1.31% SNYNF +2.94%

Sanofi (NASDAQ:SNY) is one of the Best Dip Stocks to Buy According to Hedge Funds. On February 17, Sanofi (NASDAQ:SNY) announced Manuela Buxo will replace Brian Foard as the Head of its Specialty Care Global Business Unit. Brian Foard, after serving for nearly 9 years, is leaving on February 28 to take on a leadership role elsewhere.

​Manuela Buxo will take over as the Head of Specialty Care Unit on March 1, 2026. She is currently the head of Sanofi’s (NASDAQ:SNY) Global Immunology Alliance Franchise. For the past 2 years, Buxo has been leading the worldwide strategy of Dupixent and brings over 20 years of experience in healthcare. Previously, she has served in Specialty Care roles in Europe and global franchise management.

​Management noted that Brian Foard joined Sanofi in 2017 and later assumed the position of head of Specialty Care. Under his leadership, the unit grew significantly, driven by the launch of Dupixent.

Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products. The company’s operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.

While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.